Skip to calculator

CLINICAL SCREENING · INASL 2022 · ESPEN 2020 · MASLD 2023

NAFLD / MASLD
Risk Calculator.

Fatty Liver Index (FLI) — evidence-based, non-invasive screening for hepatic steatosis (fatty liver disease) validated in the Indian population. Requires only a basic lipid panel.

FLI · Bedogni et al. 2006
Indian Validation — AUC 0.92
MASLD 2023 Criteria
No Imaging Required

Enter Lab & Measurement Values

Fields marked are required

All calculations run in your browser — no data is stored or shared.
Used for nutrition targets; not in FLI formula
📌 WHO Asian: ♂ <90 cm low · ≥90 elevated  |  ♀ <80 cm low · ≥80 elevated (INASL 2022)
Normal <150 mg/dL · High ≥200 mg/dL
Gamma-Glutamyl Transferase · Normal ♂ <65 · ♀ <35 U/L
MASLD Criteria & Risk Factors optional — for complete screening

MASLD requires hepatic steatosis + ≥1 of 5 cardiometabolic criteria (AASLD/EASL 2023). HDL-C is criterion 5:

Low HDL: ♂ <40 · ♀ <50 mg/dL = MASLD criterion 5

Independent Risk Amplifiers — Vamja et al. 2024 (Indian MAFLD cohort):

FLI · Bedogni 2006 · Indian validation: Vamja 2024 (AUC 0.92, n=500) · INASL 2022 · MASLD 2023

NAFLD / MASLD RISK SCREEN
—
FLI Score (0–100)
Awaiting input

WHAT THIS CHECKS

FLI Score (0–100)Probability of hepatic steatosis (fatty liver)
BMI + Waist RiskIndian / Asian metabolic cutoffs
Lipid ProfileTriglycerides · GGT liver enzyme
MASLD Criteria5 cardiometabolic risk factors
ESPEN Nutrition PlanMediterranean diet · macros · activity
PDF Clinical ReportSave or share with your doctor

NEED MORE?

1-on-1 Liver Health
Consultation

Our clinical dietitian will build a personalised MASLD nutrition plan based on your labs, lifestyle and comorbidities — completely free.

Book Consultation →

EVIDENCE BASE

Bedogni et al. 2006Original FLI derivation — BMC Gastroenterology
INASL 2022Indian NAFLD guidance — JCEH
ESPEN 2020/2023Nutrition in chronic liver disease
Rinella et al. 2023NAFLD → MASLD renaming — Hepatology
Vamja et al. 2024Indian validation — AUC 0.92 (n=500)

INDIAN CONTEXT

38.6% prevalenceIndia has among the world's highest NAFLD rates (INASL 2022)
Lean NAFLD16–25% of Indian NAFLD patients have BMI <23 — thin-fat phenotype
Asian BMI cutoffs≥23 overweight · ≥25 obese (vs WHO 25/30)
Fibroscan next stepCAP via Fibroscan = INASL gold-standard follow-up

⚕️ Disclaimer: FLI is a validated non-invasive screening tool for hepatic steatosis — not a diagnostic test. Liver biopsy remains the gold standard (INASL 2022). FLI ≥60 indicates high probability of fatty liver and requires clinical confirmation via USG abdomen, Fibroscan, or specialist evaluation. Not applicable during acute illness, pregnancy, or lactation. Adults 18–85 only. Does not replace clinical judgment or specialist consultation. Consult a qualified hepatologist, gastroenterologist, or registered clinical dietitian for medical decisions.